



Angiochem's ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II Trial

- Data Presented at ASCO 2016 -

MONTREAL, QC-- (Marketwired - June 6th, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, presented data during a platform presentation at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

Their lead compound, ANG1005, demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases (BCBM patients) and leptomeningeal carcinomatosis (LC).

"Our data suggests that ANG1005 has strong potential to treat relapsed BCBM patients, particularly those who also have leptomeningeal carcinomatosis (LC)" said presenter Dr. Priya Kumthekar. "Patients with LC have few alternative treatment options and we are excited about the potential efficacy of this drug to fill an unmet medical need and look forward to taking it into advanced clinical studies."

Patients with BCBM and LC also showed improved clinical symptoms and overall survival much longer than comparable historical control groups.

"The data presented at ASCO 2016 underscores our confidence in ANG1005; as such, advancing it clinically remains our top priority," said John Huss, Executive Chairman of Angiochem. "We look forward to meeting with the FDA in the near future to discuss Phase 2 results and plans for a pivotal trial."

ANG1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2) designed to cross the blood-brain barrier (BBB) and blood cerebrospinal fluid barrier (BCB) via the LRP-1 transport system.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit <http://www.angiochem.com>.

For more information, please contact:

Mr. John Huss
Executive Chairman
514-591- 7991
jhuss@angiochem.com

Crystal Quast
Bullseye Corporate
647-529- 6364
Quast@BullseyeCorporate.com